The KRAS G12D inhibitor zoldonrasib elicited responses in patients with KRAS G12D-mutated non-small cell lung cancer in a phase I clinical trial, according to results presented at AACR Annual Meeting 2025.
ALL PRODUCT PURCHASES ARE 100% TAX DEDUCTIBLE CHARITABLE DONATIONS AND GO DIRECTLY TO LIVESAVING CANCER RESEARCH. FREE SHIPPING AVAILABLE FOR ORDERS OF $75 AND UP.…
Takeaways from day three of the AACR Annual Meeting 2025 included the Opening Ceremony, a panel on cancer research at a crossroads, and more.
Several patients with AML, who were treated with SENTI-202 experienced a complete remission after not responding to or having relapsed following prior treatments, according to…
AI models, pretrained on vast datasets, significantly outperformed a standard baseline model in identifying nonmelanoma skin cancers from digital images of tissue samples, according to…
A multimodal, AI-driven model that analyzes routinely collected imaging and clinical information led to more accurate prediction of cancer cachexia than standard methods, according to…
Monday’s plenary platform will present four technologies helping to chart new horizons in oncology by advancing our understanding of cancer and developing better therapies for…
Pembrolizumab cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient early-stage solid cancers who had detectable circulating tumor DNA after…
Search for booth space by size, type or location with the exhibitor floor plan.
AACR President Patricia M. LoRusso, DO, PhD (hc), FAACR, will address efforts to accelerate research and advance personalized medicine around the world.
PD-1 immunotherapy can eliminate the need for surgery in patients with early-stage, DNA mismatch repair-deficient solid cancers, according to results presented at the AACR Annual…
